GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase 1 study, the addition of GIPR activity to GLP-1R/GCGR co-agonism was reported to greatly potentiate the weight-lowering and glycemic efficacy in overweight subjects (NCT04521738)153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, GIPR agonism within multi-receptor agonists, improves bone metabolism153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, GIP may enhance some of the effects of GLP-1 receptor agonism.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development, and are illustrated by tirzepatide”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“patients with T2DM, while GIP is almost inactive (4).”
BackgroundSelf-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 3×
“Around 1992, Raufman and Eng in New York characterized the Gila monster peptide exendin-4 (18), which turned out to be a full agonist for the GLP-1 receptor (19) (a synthetic version of which, exenatide, reached the market in 2005 (20)).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Indeed, in 2002, mice with a knockout of the GIP receptor were demonstrated to be resistant to the adipogenic effect of a high-fat diet (42), and human genetic studies identified inactivating (Rosenkilde et al, unpublished) mutations in the GIP receptor, which were associated with weight loss (43).”
BackgroundSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“erance—their contribution (via insulin secretion) to postprandial glucose clearance may be as great as to correspond to 80% of the ingested amount of glucose (1).”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 3×
“The second, tirzepatide, was clearly superior to the GLP-1 RA control, dulaglutide, in the dose-finding Phase 2 study mentioned in the beginning (7) although it was not ensured that optimal dosing had been investigated for the comparator—the fact that increasing doses of dulaglutide are currently being investigated (5…”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“The studies supporting antidiabetic and weightreducing actions of GIP and GIP co-agonists date back to an early study in rodents with a monomolecular GIPGLP-1 co-agonist, which was found to both enhance glucose tolerance and to lower body weight (39).”
BackgroundTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundSelf-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 3×
“As already alluded to, infusions of GLP-1 in supraphysiological amounts or administration of GLP-1 receptor agonists are capable of inducing insulin secretion and appetite reduction also in obese patients with T2DM, whereas infusions of GIP are remarkably ineffective, regardless of infusion rate (28).”
BackgroundVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationTurcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 409
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · cited 2×
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundSelf-citationEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 2×
“With this tool, which was administered to humans in 1998-1999 (21), it was possible to characterize the actions of endogenous GLP1, and in several studies (22,23), the insulinotropic actions of endogenous GLP-1 were confirmed using exendin 9-39, which typically reduced insulin responses to oral/intestinal glucose admi…”
BackgroundMethodAdriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 1×
“Furthermore, recent elegant studies suggested that certain somatostatinergic neurons in the rodent hypothalamus express GIP receptors and react to activation of these by decreasing food intake (45).”
BackgroundFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“Upon closer scrutiny, the first dual GIP-GLP-1 co-agonist (NN9709, formerly MAR709 and RG7697) wasn’t terribly impressive after all, and its performance in a Phase 2 clinical trial did not differ from that of liraglutide (53).”
BackgroundTargeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272 · cited 1×
“Nevertheless, it was recently shown that N-terminal modifications of exendin-4 (a strong GLP-1 receptor agonist) will turn it into a biased agonist with a lower tendency to arrestin recruitment and/or receptor internalization and therefore with potentially greater efficacy and tolerability as a therapeutic (58).”
BackgroundGIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · cited 1×
“In fact, GIP had for a long time and for many reasons been considered “the obesity hormone” (40); for instance, its secretion is enhanced by intake of fatty meals, and GIP infusions in experimental animals were reported to enhance chylomicron clearance and fat deposition (41).”
BackgroundExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · cited 2×
“With this tool, which was administered to humans in 1998-1999 (21), it was possible to characterize the actions of endogenous GLP-1, and in several studies (22,23), the insulinotropic actions of endogenous GLP-1 were confirmed using exendin 9-39, which typically reduced insulin responses to oral/intestinal glucose adm…”
BackgroundMethodMechanism of circadian variation in bone resorption
Bjarnason, N. H., Henriksen, E. E. G., Alexandersen, P., Christgau, S., Henriksen, D. B., & Christiansen, C. (2002) · Bone · doi:10.1016/s8756-3282(01)00662-7 · Cited by 262 · cited 1×
“GIP is probably one of the important actors in the so-called gut-bone axis, a term introduced to describe the 50% reduction in bone resorption (as measured by bone resorption markers; eg, C-terminal telopeptide of type 1 collagen) that occurs after food intake, compared to the fasting rate (35).”
ResultKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 7×
“e2710 J Clin Endocrinol Metab, August 2020, 105(8):e2710–e2716 https://academic.”
BackgroundResultInfluentialOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · cited 1×
“In rodents, however, long-acting GIP agonists with an improved design were recently reported to have in weight losing properties (44), and in the same series of studies long-acting (acylated) GIP antagonists did not cause weight loss in diet-induced obese animals.”
BackgroundMentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationGasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Self-citationGastric Inhibitory Polypeptide
Brown, J. C. (1982) · Monographs on endocrinology · doi:10.1007/978-3-642-81771-7 · Cited by 171
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142 · cited 1×
“In further studies of appetite and food intake, infusions of GLP-1 increased insulin secretion and inhibited food intake, whereas infusions of pharmacological amounts of GIP were ineffective and even appeared to prevent the inhibitory effects of GLP-1 on food intake (30).”
BackgroundSelf-citationCaveolin-1 Regulates Cellular Trafficking and Function of the Glucagon-Like Peptide 1 Receptor
Syme, C. A., Zhang, L., & Bisello, A. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0178 · Cited by 138 · cited 1×
“For the GLP1-1 system, receptor internalization seems independent of arrestin recruitment (57).”
BackgroundGlucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans
Nissen, A., Christensen, M., Knop, F. K., Vilsbøll, T., Holst, J. J., & Hartmann, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2547 · Cited by 135 · cited 1×
“It turns out that GIP infusions in humans are capable of causing similar reductions in bone resorption (36).”
BackgroundSelf-citationPiteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130 · cited 1×
“The inactivity of GIP in T2DM has been investigated in experimental animal models, and it has been reported that hyperglycemia reduces GIP receptor expression in the beta cells and that treatment of the hyperglycemia restores GIP receptor expression and beta cell responsiveness (32).”
BackgroundRaufman, J. P., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 122 · cited 2×
“Around 1992, Raufman and Eng in New York characterized the Gila monster peptide exendin-4 (18), which turned out to be a full agonist for the GLP-1 receptor (19) (a synthetic version of which, exenatide, reached the market in 2005 (20)).”
BackgroundEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121 · cited 2×
“While largely confirming the mimicry experiments, the use of exendin 9-39 is not unproblematic, because the antagonist also greatly increases plasma glucose and glucagon levels, which complicates the interpretation considerably (27).”
BackgroundResultSelf-citationNørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116 · cited 2×
“In addition, upon comparison of results from animal studies, it appears that almost identical results can be obtained with certain proven GIP agonists and GIP antagonists, at least with respect to their effects on body weight (8-10).”
BackgroundResultNAUCK, M., SCHMIDT, W. E., EBERT, R., STRIETZEL, J., CANTOR, P., HOFFMANN, G., & CREUTZFELDT, W. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-654 · Cited by 108 · cited 2×
“GIP, a 42-amino acid polypeptide secreted from endocrine K-cells of the upper small intestinal epithelium, was the first incretin to be established (11,12), and in careful mimicry studies, Nauck et al (13) demonstrated that the insulinotropic effects of GIP infusions, resulting in plasma concentrations similar to thos…”
BackgroundSalehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · cited 2×
“With this tool, which was administered to humans in 1998-1999 (21), it was possible to characterize the actions of endogenous GLP1, and in several studies (22,23), the insulinotropic actions of endogenous GLP-1 were confirmed using exendin 9-39, which typically reduced insulin responses to oral/intestinal glucose admi…”
BackgroundMethodMohammad, S., Patel, R. T., Bruno, J., Panhwar, M. S., Wen, J., & McGraw, T. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00256-14 · Cited by 104 · cited 2×
“Indeed, this was directly demonstrated by Mohammad et al (47), who showed that an initial GIP stimulation can impair subsequent GIP stimulations, associated with disappearance of GIPR from the plasma membrane in 3T3-L1 adipocytes.”
Hansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13384 · Cited by 98 · cited 2×
“For GIP, an effective and potent receptor antagonist for human use was only recently introduced (24), but with these tools at hand, it was now possible to analyze the combined actions of GIP and GLP-1 in the same experiment.”
BackgroundSelf-citationGabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 96 · cited 2×
“It is known that GIP activation of its receptor is associated with recruitment of beta arrestins and that arrestins are needed for the subsequent internalization of the hormone receptor complex (46).”
BackgroundSelf-citationKillion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89 · cited 2×
“In other words, the insulinotropic action of GIP may be regained after a GLP-1-mediated lowering of the blood glucose in agreement with the beneficial effects of intensive insulin therapy as previously mentioned (33).”
BackgroundSelf-citationMeier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 85
Self-citationOn the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K., Astrup, A., Flint, A., Bülow, J., & Holst, J. J. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 83 · cited 3×
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationSparre-Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 81
Self-citationGIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family
Nauck, M. A., & Meier, J. J. (2019) · Diabetes · doi:10.2337/dbi19-0005 · Cited by 65
Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62 · cited 2×
“However, the disappointing results of adding high-dose GIP infusions to chronic liraglutide treatment (31) speak against this possibility.”
BackgroundSelf-citationCharacterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1
Hager, M. V., Clydesdale, L., Gellman, S. H., Sexton, P. M., & Wootten, D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.018 · Cited by 59 · cited 1×
“In fact, it has been shown that even small changes in the GIP as well as the GLP-1 molecule may change the receptor signaling towards a preferential G protein signaling with decreased arrestin recruitment and/or reduced receptor internalization (for GIP changes, see (51); for GLP-1 changes, (55, 56)).”
BackgroundGabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & Rosenkilde, M. M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55 · cited 2×
“For instance, when studied in vitro, the well-known GIP receptor mutation E354Q, which is associated with impaired glucose tolerance and increased fracture risk in postmenopausal women (49), actually shows enhanced agonist-mediated and basal 3′,5′-cyclic AMP formation and maintained arrestin recruitment, but prolonged…”
BackgroundSelf-citationIsmail, S., Ghérardi, M.-J., Froese, A., Zanoun, M., Gigoux, V., Clerc, P., Gaits‐Iacovoni, F., Steyaert, J., Nikolaev, V. O., & Fourmy, D. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.009 · Cited by 54 · cited 1×
“This mutation is also associated with a slower recycling of internalized receptors to the cell surface, which, although it has been shown that the GIP receptor may also signal from endosomes (52), probably contributes to an overall impaired receptor function.”
BackgroundFrias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 46
GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2
Gasbjerg, L. S., Hartmann, B., Christensen, M. B., Lanng, A. R., Vilsbøll, T., Jørgensen, N. R., Holst, J. J., Rosenkilde, M. M., & Knop, F. K. (2020) · Bone · doi:10.1016/j.bone.2019.115079 · Cited by 40 · cited 1×
“In agreement with the supposed actions of GIP, administration of the GIP antagonist GIP (3–29) NH2 greatly reduced the meal-induced suppression of bone resorption, and these experiments thus confirmed the important contribution of GIP to the gut-bone axis (37).”
BackgroundSelf-citationFrémaux, J., Venin, C., Mauran, L., Zimmer, R., Koensgen, F., Rognan, D., Bitsi, S., Lucey, M., Jones, B. J., Tomás, A., et al. (2019) · Chemical Science · doi:10.1039/c9sc02079a · Cited by 35 · cited 1×
“In fact, it has been shown that even small changes in the GIP as well as the GLP-1 molecule may change the receptor signaling towards a preferential G protein signaling with decreased arrestin recruitment and/or reduced receptor internalization (for GIP changes, see (51); for GLP-1 changes, (55, 56)).”
BackgroundIsmail, S., Dubois-Vedrenne, I., Laval, M., Tikhonova, I. G., D’Angelo, R., Sanchez, C., Clerc, P., Ghérardi, M.-J., Gigoux, V., Magnan, R., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.001 · Cited by 34 · cited 3×
“In fact, it has been shown that even small changes in the GIP as well as the GLP-1 molecule may change the receptor signaling towards a preferential G protein signaling with decreased arrestin recruitment and/or reduced receptor internalization (for GIP changes, see (51); for GLP-1 changes, (55, 56)).”
BackgroundAl-Zamel, N., Al‐Sabah, S., Luqmani, Y. A., Adi, L., Chacko, S., Schneider, T. D., & Krasel, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143532 · Cited by 25 · cited 1×
“A similar alteration in GLP-1 receptor signaling profile was recently established for a dual acting GIP-GLP-1 peptide (59).”
BackgroundTorekov, S. S., Ma, L., Grarup, N., Hartmann, B., Hainerová, I. A., Kielgast, U. L., Kissow, H., ROSENKILDE, M. M., Lebl, J., Witte, D. R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2265-7 · Cited by 19
Self-citationBrown, J. C. (1982) · Monographs on endocrinology · doi:10.1007/978-3-642-81771-7_1 · Cited by 10
Research works printed but not linked: 2
- Stensen, 2019, Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific effects in obese patients with type 2 diabetes, Diabetologia., 62, S270
- Marks, 1988, GIP: the obesity hormone., 13
Cited by
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Lister, N. B., Baur, L. A., Felix, J. F., Hill, A. J., Marcus, C., Reinehr, T., Summerbell, C., & Wabitsch, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00435-4 · Cited by 500
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Agonist-induced GIPR desensitization has been proposed as a potential unifying mechanism to explain this paradoxical observation [91,92], raising the fascinating possibility that we may witness the development of competing therapeutic strategies based on either GIPR agonism or antagonism, together with GLP-1R agonism,…”
Background
Metadata
- Authors
- Holst, J. J., & Rosenkilde, M. M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens Juul
- Rosenkilde, Mette Marie
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-05-27
- Volume
- 105
- Issue
- 8
- Pages
- e2710-e2716
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7308078
- OpenAlex
- W3030023482
- Cited by
- 207
- References
- 60
- Citations by year
- 2026: 32 · 2025: 36 · 2024: 39 · 2023: 28 · 2022: 40 · 2021: 26 · 2020: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, type 2 diabetes, obesity, GIP receptor antagonist, receptor internalization, ligand structure, insulin secretion, weight loss treatment, receptor signaling
- MeSH terms
- Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.